A5078493524- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Bladder and Urothelial Cancer Treatments
- Biomedical Ethics and Regulation
- Viral-associated cancers and disorders
- Immunotherapy and Immune Responses
- Ovarian cancer diagnosis and treatment
- Appendicitis Diagnosis and Management
- Polyomavirus and related diseases
- Cancer Cells and Metastasis
- Intraperitoneal and Appendiceal Malignancies
- Cutaneous Melanoma Detection and Management
- Lymphoma Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
University of California, Los Angeles
2024-2025
Ronald Reagan UCLA Medical Center
2024
Loma Linda University
2020-2021
Loma Linda University Health Care
2020
TPS788 Background: MSLN is a desirable candidate for targeted therapy given its limited expression in normal tissues and overexpression several malignancies, including PANC, mesothelioma, non-small cell lung, ovarian cancers (TCGA 2022). MSLN-targeted CAR T T-cell receptor therapies have shown promising clinical activity; however, on-target, off-tumor toxicity, fatal events, occurred (1-3). Autologous logic-gated Tmod address the challenges of toxicity by combining 2 CARs: activating...
Post-transplant lymphoproliferative disorders (PTLDs) are lymphoid or plasmacytic proliferations ranging from polyclonal reactive to overt lymphomas that develop as consequence of immunosuppression in recipients solid organ transplantation (SOT) allogeneic bone marrow/hematopoietic stem cell transplantation. Immunosuppression and Epstein–Barr virus (EBV) infection known risk factors for PTLD. Patients with documented histopathologic diagnosis primary PTLD at our institution between January...
Abstract Introduction: Even after curative intent resection, stage III melanoma carries poor prognosis and traditional chemotherapy has limited efficacy. Adjuvant immune checkpoint inhibitor (ICI) therapy utilizing the anti-CTLA-4 agent, ipilimumab, was shown to improve survival following resection in Stage disease. Ipilimumab FDA approved for adjuvant 2015. The National Cancer Database (NCDB) is a joint project of Commission on American College Surgeons Society largest clinical cancer...
3626 Background: Adenocarcinoma of the appendix (AAC) is a rare form intestinal malignancy that can pursue an aggressive clinical course. Little known about and biologic features this disease when it presents in young patients under 40. Methods: 1,840 cases clinically advanced AAC were selected analyzed by hybrid capture based comprehensive genomic profiles (CGP) to evaluate all classes alterations (GA). MSI high status tumor mutation burden (TMB) determined from sequencing results PD-L1 was...
<h3>Background</h3> Chimeric antigen receptor T-cell (CAR T) therapy in solid tumors has been challenging, part, owing to a lack of tumor-specific targets that discriminate cancer from normal cells resulting dose-limiting, on-target, off-tumor toxicities.<sup>1 2</sup> A2B530 is logic-gated carcinoembryonic (CEA)-targeting Tmod<sup>TM</sup> CAR T being evaluated the EVEREST-1 (NCT05736731) first-in-human study. Tmod addresses challenges toxicity by combining CEA-targeted CAR-activating with...
Abstract Background Immune checkpoint inhibitors (ICI) have become a mainstay treatment of variety advanced malignancies, prolonging survival. There are no serologic markers to predict response ICI, but some small series suggested eosinophilia predicts improved Methods This is an IRB approved single-center retrospective observational study including all patients (n= 80) from 2014-2019 who received ICI for non-hematologic malignancies at Loma Linda University Medical Center. Data were...